Citigroup Initiates Coverage On Xenon Pharmaceuticals with Buy Rating, Announces Price Target of $62
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang has initiated coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and set a price target of $62.

January 04, 2024 | 9:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst David Hoang initiated coverage on Xenon Pharmaceuticals with a Buy rating and a price target of $62.
Analyst coverage, especially with a Buy rating, typically generates positive investor sentiment and can lead to a short-term increase in stock price. The price target of $62 suggests significant upside potential from the current trading price, which may attract investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100